Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine



Rating:

Share or cite this content

Citations should be made in the following way:
Daan Hurkmans (Netherlands), Joachim Aerts (Netherlands). How does the cancer immunity circle operate (or dysoperate)?. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003 Screening for lung cancer: who should (not) be enrolled? Source: International Congress 2019 – NELSON: the Trafalgar of lung cancer screening? Year: 2019 Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST). Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006 Surgery for non small cell lung cancer (NSCLC) and functional limits: is there a possible beneficial role of preoperative pulmonary rehabilitation? Source: Eur Respir J 2004; 24: Suppl. 48, 522s Year: 2004 LSC - 2020 - Comprehensive characterization of the immune landscape within different molecular subtypes of small cell lung cancer (SCLC) Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Ageing of the immune system: a contribution to lung disease? Source: Annual Congress 2012 - Searching for the secrets of senescence in the lung Year: 2012 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The lung cancer microenvironment and the lung microbioma: cross or cease fire? Source: Virtual Congress 2020 – Exciting new developments in lung cancer screening, diagnostics and treatment Year: 2020 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Cytotoxic T cell antigen 4 and the status of T cell activation in lung cancer: local vs. systemic immune response. Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 LSC 2013 abstract - Host defense against pneumonia: The role of the leptin/neutrophil axis? Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Do antimicrobial peptides shape the adaptive immune response? Source: Annual Congress 2005 - Interaction between innate and adaptive immunity in lung disease Year: 2005 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Phenotype pattern of human non-small cell lung cancer (NSCLC) model line in immune escape phenomenon. Effect of transfection with plasmids encoding specific anti-EGFR1 and anti-HER2/neu short hairpin (SH)RNA sequences Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 MiR-34a favours macrophage polarization switch from M2 to M1 phenotype in non small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020